Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DXCM DexCom	$82.99 -2.2%	$77.65	$57.52 ▼ $118.80	$32.54B	1.46	4.32 million shs	3.24 million shs
MASI Masimo	$167.01 -0.6%	$157.82	$101.61 ▼ $194.88	$9.06B	1.19	643,860 shs	617,703 shs
RMD ResMed	$251.18 -0.6%	$235.14	$179.42 ▼ $263.05	$36.83B	0.78	1.01 million shs	620,274 shs
STE STERIS	$240.70 -0.7%	$231.51	$200.98 ▼ $252.79	$23.68B	0.94	547,688 shs	471,829 shs

20 Stocks to Sell Now

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DXCM DexCom	-2.16%	-3.06%	-2.42%	+21.19%	-29.01%
MASI Masimo	-0.61%	+2.49%	+2.11%	+0.80%	+34.50%
RMD ResMed	-0.56%	+0.51%	+1.40%	+14.53%	+19.51%
STE STERIS	-0.65%	-0.58%	+3.35%	+8.23%	+6.80%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DXCM DexCom	4.7547 of 5 stars	3.5	5.0	0.0	4.7	1.5	2.5	1.9
MASI Masimo	4.1718 of 5 stars	3.4	1.0	0.0	4.2	1.5	3.3	1.3
RMD ResMed	4.0743 of 5 stars	2.3	1.0	3.3	4.6	2.3	1.7	1.3
STE STERIS	4.5564 of 5 stars	2.3	5.0	3.3	3.8	1.8	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DXCM DexCom	2.95	Moderate Buy	$98.32	18.47% Upside
MASI Masimo	2.83	Moderate Buy	$191.60	14.72% Upside
RMD ResMed	2.60	Moderate Buy	$259.33	3.25% Upside
STE STERIS	2.63	Moderate Buy	$263.83	9.61% Upside

Current Analyst Ratings Breakdown

Latest MASI, RMD, DXCM, and STE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/30/2025	DXCM DexCom	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$104.00
5/29/2025	STE STERIS	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold	$263.00
5/22/2025	DXCM DexCom	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$82.00 ➝ $102.00
5/20/2025	RMD ResMed	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Overweight	$286.00
5/19/2025	STE STERIS	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$240.00 ➝ $260.00
5/16/2025	STE STERIS	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/16/2025	STE STERIS	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$265.00 ➝ $280.00
5/15/2025	STE STERIS	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$250.00 ➝ $250.00
5/7/2025	MASI Masimo	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$193.00
5/7/2025	MASI Masimo	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$215.00 ➝ $200.00
5/7/2025	MASI Masimo	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$204.00 ➝ $185.00

(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DXCM DexCom	$4.15B	7.84	$2.09 per share	39.75	$5.38 per share	15.43
MASI Masimo	$2.13B	4.26	$5.43 per share	30.74	$25.79 per share	6.48
RMD ResMed	$5.02B	7.33	$9.96 per share	25.23	$35.77 per share	7.02
STE STERIS	$5.46B	4.34	$15.30 per share	15.73	$65.43 per share	3.68

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DXCM DexCom	$576.20M	$1.34	58.03	33.74	2.30	14.29%	30.14%	10.11%	7/24/2025 (Estimated)
MASI Masimo	$81.50M	-$9.17	115.18	36.07	N/A	3.85%	14.98%	6.95%	8/5/2025 (Estimated)
RMD ResMed	$1.02B	$8.91	29.65	24.24	1.53	25.34%	26.17%	18.60%	7/30/2025 (Estimated)
STE STERIS	$378.24M	$6.20	51.10	24.24	N/A	8.66%	13.91%	8.64%	8/5/2025 (Estimated)

Latest MASI, RMD, DXCM, and STE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q4 2025	STE STERIS	$2.59	$2.74	+$0.15	$1.47	$1.47 billion	$1.48 billion
5/6/2025	Q1 2025	MASI Masimo	$1.24	$1.36	+$0.12	-$3.12	$367.79 million	$372.00 million
5/1/2025	Q1 2025	DXCM DexCom	$0.33	$0.32	-$0.01	$0.27	$1.02 billion	$1.04 billion
4/23/2025	Q3 2025	RMD ResMed	$2.36	$2.37	+$0.01	$2.48	$1.28 billion	$1.29 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DXCM DexCom	N/A	N/A	N/A	N/A	N/A
MASI Masimo	N/A	N/A	N/A	N/A	N/A
RMD ResMed	$2.12	0.84%	N/A	23.79%	13 Years
STE STERIS	$2.28	0.95%	N/A	36.77%	20 Years

Latest MASI, RMD, DXCM, and STE Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/7/2025	STE STERIS	quarterly	$0.57	1.01%	6/10/2025	6/10/2025	6/26/2025
4/24/2025	RMD ResMed	quarterly	$0.53	0.9%	5/8/2025	5/8/2025	6/12/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DXCM DexCom	0.59	1.47	1.28
MASI Masimo	0.50	2.01	1.11
RMD ResMed	0.13	3.33	2.29
STE STERIS	0.32	2.13	1.40

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DXCM DexCom	97.75%
MASI Masimo	85.96%
RMD ResMed	54.98%
STE STERIS	94.69%

Insider Ownership

Company	Insider Ownership
DXCM DexCom	0.32%
MASI Masimo	16.90%
RMD ResMed	0.71%
STE STERIS	1.14%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DXCM DexCom	7,600	392.11 million	389.60 million	Optionable
MASI Masimo	6,200	54.22 million	48.35 million	Optionable
RMD ResMed	8,160	146.63 million	145.82 million	Optionable
STE STERIS	16,000	98.37 million	97.13 million	Optionable

MASI, RMD, DXCM, and STE Headlines

Recent News About These Companies

Avanza Fonder AB Invests $2 Million in STERIS plc (NYSE:STE)

June 12 at 5:25 AM | marketbeat.com

Wedmont Private Capital Makes New Investment in STERIS plc (NYSE:STE)

June 12 at 4:02 AM | marketbeat.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Steris (STE) and Apellis Pharmaceuticals (APLS)

June 11 at 10:13 PM | theglobeandmail.com

Equities Analysts Offer Predictions for STERIS Q1 Earnings

June 10 at 1:37 AM | americanbankingnews.com

STERIS plc (NYSE:STE) Shares Purchased by Fenimore Asset Management Inc

June 9 at 7:14 AM | marketbeat.com

Zacks Research Comments on STERIS's Q1 Earnings (NYSE:STE)

June 9 at 1:36 AM | marketbeat.com

Gateway Investment Advisers LLC Trims Position in STERIS plc (NYSE:STE)

June 8, 2025 | marketbeat.com

Congress Asset Management Co. Raises Stock Position in STERIS plc (NYSE:STE)

June 8, 2025 | marketbeat.com

STERIS plc (NYSE:STE) CEO Sells $4,275,362.56 in Stock

June 8, 2025 | americanbankingnews.com

Narrow-Moat Steris’ Leadership in Sterilization Positions the Company for Future Growth

June 8, 2025 | morningstar.com

Blue Zone Wealth Advisors LLC Raises Stake in STERIS plc (NYSE:STE)

June 7, 2025 | marketbeat.com

Unique Wealth LLC Invests $268,000 in STERIS plc (NYSE:STE)

June 7, 2025 | marketbeat.com

Zacks Research Has Bearish Forecast for STERIS Q2 Earnings

June 7, 2025 | americanbankingnews.com

STERIS plc (Ireland) (STE) Stock Forecasts

June 7, 2025 | finance.yahoo.com

Daniel A. Carestio Sells 17,626 Shares of STERIS plc (NYSE:STE) Stock

June 6, 2025 | marketbeat.com

Zacks Research Has Negative Estimate for STERIS Q2 Earnings

June 6, 2025 | marketbeat.com

STE Q1 Earnings Call: STERIS Outpaces Profit Expectations, Faces Revenue Headwinds and Tariff Uncertainty

June 4, 2025 | finance.yahoo.com

Czech National Bank Boosts Stake in STERIS plc (NYSE:STE)

June 4, 2025 | marketbeat.com

Rhumbline Advisers Buys 11,921 Shares of STERIS plc (NYSE:STE)

June 4, 2025 | marketbeat.com

STERIS plc (NYSE:STE) Shares Bought by Strong Tower Advisory Services

June 2, 2025 | marketbeat.com

GAMMA Investing LLC Grows Position in STERIS plc (NYSE:STE)

June 2, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MASI, RMD, DXCM, and STE Company Descriptions

DexCom NASDAQ:DXCM

$82.99 -1.83 (-2.16%)

Closing price 06/11/2025 04:00 PM Eastern

Extended Trading

$82.99 0.00 (0.00%)

As of 04:00 AM Eastern

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Masimo NASDAQ:MASI

$167.01 -1.02 (-0.61%)

Closing price 06/11/2025 04:00 PM Eastern

Extended Trading

$167.01 0.00 (0.00%)

As of 04:18 AM Eastern

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry. It also provides brain function and hemodynamic monitoring solutions; patient position and activity tracking, and neuromodulation technology solutions; and Masimo Hospital Automation platform, including hospital automation solutions, including Patient SafetyNet, Patient SafetyNet Surveillance, SafetyNet, Replica, Iris, MyView, UniView, Uniview: 60, Masimo Sleep, Centroid, and Bridg; and nasal high-flow ventilation, neuromodulation therapeutics, and telehealth solutions. In addition, the company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers; and home wellness products through e-commerce internet sites, such as masimopersonalhealth.com, amazon.com, and shopify.com. Masimo Corporation was incorporated in 1989 and is headquartered in Irvine, California.

ResMed NYSE:RMD

$251.18 -1.48 (-0.59%)

Closing price 06/11/2025 03:59 PM Eastern

Extended Trading

$251.36 +0.18 (+0.07%)

As of 04:00 AM Eastern

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

STERIS NYSE:STE

$240.70 -1.67 (-0.69%)

Closing price 06/11/2025 03:59 PM Eastern

Extended Trading

$240.74 +0.05 (+0.02%)

As of 04:46 AM Eastern

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier, sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The Dental segment provides hand and electric-powered dental instruments, infection control products, conscious sedation, personal protective equipment, and water quality products for dental suite. The company serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is based in Dublin, Ireland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time